KR100635703B1 - 세포 이동성 검사 - Google Patents
세포 이동성 검사 Download PDFInfo
- Publication number
- KR100635703B1 KR100635703B1 KR1020067007834A KR20067007834A KR100635703B1 KR 100635703 B1 KR100635703 B1 KR 100635703B1 KR 1020067007834 A KR1020067007834 A KR 1020067007834A KR 20067007834 A KR20067007834 A KR 20067007834A KR 100635703 B1 KR100635703 B1 KR 100635703B1
- Authority
- KR
- South Korea
- Prior art keywords
- cell
- cell migration
- receptor
- chemokine
- cells
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
- Spectrometry And Color Measurement (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
수용체 | 리간드 예2 |
BLT1 | 루코트리엔 B4 |
PDGFR | 혈소판-유도된 생장 인자 |
FPR | fMLP |
FPR1 | 모름 |
FMLP 수용체-유사 수용체 | 모름 |
CRTH2 | 프로스타글란딘2 |
C3aR | C3a |
C5aR | C5a |
Noci-R | 노시페틴 |
EDG 패밀리 | 스핑고신 1-인산염 |
CB1 | 카나비노이드 |
VEGFR | 맥관 내피 생장 인자 |
EGFR | 상피 생장 인자 |
FGFR | 섬유아세포 생장 인자 |
P2Y 수용체 | P2Y |
CTR | 칼시토닌 |
CRLR | 칼시토닌 유전자관련 펩티드(CGRP) |
히스타민 수용체 | 히스타민 |
트롬빈 수용체 | 트롬빈 |
TrkB | 뇌-유도된 신경성 생장인자(BDNF) |
1화학친화성물질 수용체는 완벽한 것은 아니다. 2각 수용체에 대한 일부 리간드의 예만을 제공한다. 이 목록이 완벽하다는 것을 의미하는 것은 아니다. |
수용체 | 사람 리간드 |
CXCR1 | IL-8, GCP-2 |
CXCR2 | IL-8, GCP-2, Gro α, Gro β, Gro γ, ENA-78, PBP |
CXCR3 | MIG IP-10, I-TAC |
CXCR4 | SDF-1/PBSF |
CXCR5 | BLC/BCA-1 |
CCR1 | MIP-1α, MIP1-β, RANTES, HCC-1,2,3, 4 |
CCR2 | MCP-2, MCP-2, MCP-3, MCP-4 |
CCR3 | 이오탁신(eotaxin)-1, eotaxin-2, MCP-3 |
CCR4 | TARC, MDC, MIP-1α, RANTES |
CCR5 | MIP-1α MIP-1β, RANTES |
CCR6 | MIP-3α/LARC |
CCR7 | MIP-3β/ELC, 6Ckine/LC |
CCR8 | I-309 |
CCR9 | TECK |
XCR1 | 임포탁틴 |
CX3CR1 | 프랙트알킨/뉴우로택틴 |
CXCR6 | CXCL16 |
CCR10 | CTACK |
길항제1 | 수용체 | 리간드 | 세포 |
RAMAG-1 | CXCR3 | I-TAC(250nM), IP-10 | 활성화된 사람 임파세포 |
RAMAG-2 | CXCR4 | SDF-1 | CXCR4를 발현하는 MOLT-4 세포 (사람 T 임파아구; American Type Tissue Collection(ATCC); Manassas, VA) |
RAMAG-3 | CCR1 | MIP-1α | THP-1 세포(사람 단세포; ATCC) |
1통상적인 세포 이동 검사를 이용하여 확인하였고, 추가 별도 확인 2실시예 1에서 설명하는 것과 같이 결정된 저해 농도 |
Claims (2)
- 새로운 화학주성인자 수용체 길항제를 확인하고 구별하기 위한 키트에 있어서, 아래와 같이 구성되는 것을 특징으로 하는 키트:a) 화학주성인자 수용체-보유 세포에 대한 세포-이동 저해 농도의 리간드를 함유하는 용액, 여기서 상기 리간드의 세포-이동 저해 농도는 0.1 nM 내지 10 mM이고;b) 후보 길항제가 실제 길항제임을 확인하기 위한 아래와 같이 구성되는 세포 이동 장치:- 후보 길항제와 함께 화학주성인자 수용체-보유 세포를 배양하기 위한 제 1 쳄버,- 세포-이동 저해 농도의 리간드를 함유하는 용액을 수용하기 위한 제 2 쳄버, 여기서 화학주성인자 수용체-보유 세포는 제 1 쳄버로부터 제 2 쳄버로 이동하고, 세포-이동 저해 농도의 리간드는 화학주성인자 수용체-보유 세포의 제 1 쳄버로부터 제 2 쳄버로의 이동을 저해하고;여기서, 후보 길항제와 세포-이동 저해 농도의 리간드의 존재하에 화학주성인자 수용체-보유 세포의 제 2 쳄버로의 증가된 이동은 후보 길항제를 실제 길항제로서 확인한다.
- 제 1항에 있어서, 용액은 동결 건조되는 것을 특징으로 하는 키트.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29668201P | 2001-06-07 | 2001-06-07 | |
US60/296,682 | 2001-06-07 | ||
US10/154,399 | 2002-05-22 | ||
US10/154,399 US7282338B2 (en) | 2001-06-07 | 2002-05-22 | Cell migration assay |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037015768A Division KR100598309B1 (ko) | 2001-06-07 | 2002-05-22 | 세포 이동성 검사 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060054488A KR20060054488A (ko) | 2006-05-22 |
KR100635703B1 true KR100635703B1 (ko) | 2006-10-17 |
Family
ID=26851415
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067007834A KR100635703B1 (ko) | 2001-06-07 | 2002-05-22 | 세포 이동성 검사 |
KR1020037015768A KR100598309B1 (ko) | 2001-06-07 | 2002-05-22 | 세포 이동성 검사 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037015768A KR100598309B1 (ko) | 2001-06-07 | 2002-05-22 | 세포 이동성 검사 |
Country Status (11)
Country | Link |
---|---|
US (3) | US7282338B2 (ko) |
EP (2) | EP1417488B1 (ko) |
JP (2) | JP4233092B2 (ko) |
KR (2) | KR100635703B1 (ko) |
AT (1) | ATE347695T1 (ko) |
CA (1) | CA2449628C (ko) |
DE (1) | DE60216606T2 (ko) |
DK (1) | DK1417488T3 (ko) |
ES (1) | ES2274041T3 (ko) |
HK (1) | HK1065844A1 (ko) |
WO (1) | WO2002101350A2 (ko) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100635703B1 (ko) * | 2001-06-07 | 2006-10-17 | 케모센트릭스, 인크. | 세포 이동성 검사 |
WO2004024075A2 (en) * | 2002-09-11 | 2004-03-25 | Medical College Of Georgia Research Institute, Inc. | Chemokine receptor antagonists as therapeutic agents |
US7919083B2 (en) * | 2002-11-15 | 2011-04-05 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
CN101077867B (zh) | 2002-11-18 | 2012-10-10 | 坎莫森特里克斯公司 | 芳基磺酰胺 |
CN1914313A (zh) * | 2004-02-13 | 2007-02-14 | 旭科技玻璃股份有限公司 | 胚胎干细胞用喂食细胞培育培养基及喂食细胞 |
US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
ATE503741T1 (de) | 2005-01-14 | 2011-04-15 | Chemocentryx Inc | Heteroarylsulfonamide und ccr2 |
US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
PT2046762E (pt) | 2006-07-14 | 2011-05-23 | Chemocentryx Inc | ?triazolilfenilbenzenossulfonamidas |
BRPI0714844B8 (pt) * | 2006-07-18 | 2023-04-18 | Noxxon Pharma Ag | molécula de ácido nucleico e seus usos, composição farmaceutica e complexo |
CA2692761C (en) | 2007-07-12 | 2013-04-30 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation |
AU2008285939B2 (en) * | 2007-08-06 | 2014-09-18 | TME Pharma AG | SDF-1 binding nucleic acids and the use thereof |
AU2011300818B2 (en) | 2010-09-09 | 2015-11-12 | TME Pharma AG | SDF-1 binding nucleic acids and the use thereof in cancer treatment |
MX361929B (es) | 2010-11-19 | 2018-12-19 | Eisai R&D Man Co Ltd Star | Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes. |
CN104849377A (zh) * | 2015-01-29 | 2015-08-19 | 衢州市质量技术监督检测中心 | 一种气质法快速测定畜禽肉中β-兴奋剂的前处理方法 |
MX2019005810A (es) | 2016-11-23 | 2019-09-11 | Chemocentryx Inc | Método para tratar glomeruloesclerosis segmentaria focal. |
JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
WO2019075086A1 (en) | 2017-10-11 | 2019-04-18 | Chemocentryx, Inc. | TREATMENT OF FOCAL SEGMENTAL GLOBEROSCLEROSIS WITH CCR2 ANTAGONISTS |
US11995833B2 (en) | 2020-07-31 | 2024-05-28 | The Joan and Irwin Jacobs Technion-Cornell Institute | System and method for on-phase microscopy |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5284753A (en) | 1991-03-20 | 1994-02-08 | Neuro Probe, Inc. | Multiple-site chemotactic test apparatus and method |
SE9600820D0 (sv) * | 1996-03-01 | 1996-03-01 | Pharmacia Ab | Antibodies and their use |
US5928881A (en) * | 1996-07-11 | 1999-07-27 | Smithkline Beecham Corporation | Method of identifying agonists and antagonist for CC-CKR5 receptor |
GB9617923D0 (en) * | 1996-08-28 | 1996-10-09 | Smithkline Beecham Plc | Novel receptor |
US6153441A (en) * | 1998-02-17 | 2000-11-28 | Smithkline Beecham Corporation | Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof |
US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
US6649158B1 (en) * | 1998-10-15 | 2003-11-18 | Canji, Inc. | Methods and compositions to induce antitumor response |
AU2030000A (en) | 1998-11-25 | 2000-06-13 | Cadus Pharmaceutical Corporation | Methods and compositions for identifying receptor effectors |
US6329159B1 (en) | 1999-03-11 | 2001-12-11 | Millennium Pharmaceuticals, Inc. | Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function |
AU4230900A (en) * | 1999-04-08 | 2000-10-23 | General Hospital Corporation, The | Purposeful movement of human migratory cells away from an agent source |
KR100635703B1 (ko) * | 2001-06-07 | 2006-10-17 | 케모센트릭스, 인크. | 세포 이동성 검사 |
-
2002
- 2002-05-22 KR KR1020067007834A patent/KR100635703B1/ko active IP Right Grant
- 2002-05-22 EP EP02739361A patent/EP1417488B1/en not_active Expired - Lifetime
- 2002-05-22 ES ES02739361T patent/ES2274041T3/es not_active Expired - Lifetime
- 2002-05-22 DK DK02739361T patent/DK1417488T3/da active
- 2002-05-22 US US10/154,399 patent/US7282338B2/en not_active Expired - Lifetime
- 2002-05-22 WO PCT/US2002/016325 patent/WO2002101350A2/en active IP Right Grant
- 2002-05-22 JP JP2003504063A patent/JP4233092B2/ja not_active Expired - Lifetime
- 2002-05-22 CA CA002449628A patent/CA2449628C/en not_active Expired - Lifetime
- 2002-05-22 AT AT02739361T patent/ATE347695T1/de active
- 2002-05-22 KR KR1020037015768A patent/KR100598309B1/ko active IP Right Grant
- 2002-05-22 EP EP06017100A patent/EP1717583A3/en not_active Withdrawn
- 2002-05-22 DE DE60216606T patent/DE60216606T2/de not_active Expired - Lifetime
-
2004
- 2004-11-08 HK HK04108760A patent/HK1065844A1/xx not_active IP Right Cessation
-
2005
- 2005-01-24 US US11/041,858 patent/US20050186556A1/en not_active Abandoned
-
2007
- 2007-04-17 US US11/788,334 patent/US7396653B2/en not_active Expired - Lifetime
-
2008
- 2008-06-18 JP JP2008158580A patent/JP4340713B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP4340713B2 (ja) | 2009-10-07 |
KR20040012888A (ko) | 2004-02-11 |
JP2009000113A (ja) | 2009-01-08 |
ATE347695T1 (de) | 2006-12-15 |
CA2449628A1 (en) | 2002-12-19 |
EP1717583A2 (en) | 2006-11-02 |
US20030017485A1 (en) | 2003-01-23 |
DE60216606T2 (de) | 2007-04-05 |
HK1065844A1 (en) | 2005-03-04 |
WO2002101350A2 (en) | 2002-12-19 |
JP4233092B2 (ja) | 2009-03-04 |
US7282338B2 (en) | 2007-10-16 |
ES2274041T3 (es) | 2007-05-16 |
JP2005518184A (ja) | 2005-06-23 |
DK1417488T3 (da) | 2007-03-05 |
DE60216606D1 (de) | 2007-01-18 |
KR20060054488A (ko) | 2006-05-22 |
US20050186556A1 (en) | 2005-08-25 |
US20070196855A1 (en) | 2007-08-23 |
KR100598309B1 (ko) | 2006-07-10 |
US7396653B2 (en) | 2008-07-08 |
WO2002101350A3 (en) | 2004-03-11 |
EP1417488A2 (en) | 2004-05-12 |
EP1717583A3 (en) | 2007-10-10 |
EP1417488B1 (en) | 2006-12-06 |
EP1417488A4 (en) | 2004-07-14 |
CA2449628C (en) | 2008-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7396653B2 (en) | Cell migration assay | |
Pelletier et al. | Presentation of chemokine SDF-1α by fibronectin mediates directed migration of T cells | |
US7468253B2 (en) | Method for multiple chemokine receptor screening for antagonists using RAM assay | |
Rodríguez-Frade et al. | Similarities and Differences in RANTES-and (AOP)-RANTES–triggered Signals: Implications for Chemotaxis | |
Muri et al. | Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course | |
Sachpatzidis et al. | Identification of allosteric peptide agonists of CXCR4 | |
Brandes et al. | Activation-dependent modulation of B lymphocyte migration to chemokines | |
Soriano et al. | Functional inactivation of CXC chemokine receptor 4–mediated responses through SOCS3 up-regulation | |
Ikegawa et al. | Elevated plasma stromal cell-derived factor 1 protein level in the progression of HIV type 1 infection/AIDS | |
Song et al. | Regulation of the oligomeric status of CCR3 with binding ligands revealed by single-molecule fluorescence imaging | |
Cludts et al. | Detection of neutralizing interleukin-17 antibodies in autoimmune polyendocrinopathy syndrome-1 (APS-1) patients using a novel non-cell based electrochemiluminescence assay | |
AU2003266749B2 (en) | Method for Multiple Chemokine Receptor Screening for Antagonists Using RAM Assay | |
AU2002312014A1 (en) | Cell migration assay | |
CA2452254C (en) | Method for multiple chemokine receptor screening for antagonists using ram assay | |
AU2006200356A1 (en) | Method for multiple chemokine receptor screening for antagonists using RAM assay | |
Ott et al. | A high-throughput chemotaxis assay for pharmacological characterization of chemokine receptors: Utilization of U937 monocytic cells | |
Kershaw et al. | Analysis of chemokine receptor endocytosis and intracellular trafficking | |
Mack et al. | Downmodulation and recycling of chemokine receptors | |
Taub et al. | Biological responses to chemokine superfamily members | |
Islam et al. | Chemokine and chemokine receptor analysis | |
Blanco et al. | Multiparametric assay to screen and dissect the mode of action of anti-human immunodeficiency virus envelope drugs | |
Proudfoot et al. | Cellular assays of chemokine receptor activation | |
Torbati et al. | Methods to Assess Chemokine Binding and Anti-chemotactic Activity of Virus Proteins | |
Fuentes | Discovery of Small-Molecule Antagonists of Chemokine Receptors: Screening Strategy and Assays | |
Ribeiro et al. | Pharmaceutical targeting of chemokine receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120927 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20130927 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140929 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20151001 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160929 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20171010 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20181002 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190924 Year of fee payment: 14 |